CoChat

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Faivre, Sandrine, Santoro, Armando, Kelley, Robin K., Gane, Ed, Costentin, Charlotte E., Gueorguieva, Ivelina, Smith, Claire, Cleverly, Ann, Lahn, Michael M., Raymond, Eric, Benhadji, Karim A., Giannelli, Gianluigi · 2019 · Liver International
Cited by 142

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Background and Aims: We assessed the activity of galunisertib, a small molecule inhibitor of the transforming growth factor beta (TGF‐β1) receptor I, in second‐line patients with hepatocellular carcinoma (HCC) in two cohorts of baseline serum alpha fetoprotein (AFP). Methods: Patients with advanced HCC who progressed on or were ineligible to receive sorafenib, Child‐Pugh A/B7 and ECOG PS ≤1 were enrolled into Part A (AFP ≥ 1.5× ULN) or Part B (AFP < 1.5× ULN). Patients were treated with 80 or 150 mg galunisertib BID for 14 days per 28‐day cycle. Endpoints were time‐to‐progression (TTP) and changes in circulating AFP and TGF‐β1 levels, as well as safety, pharmacokinetics, progression‐free survival and overall survival (OS). Results: Patients (n = 149) were enrolled with median age 65 years. Median TTP was 2.7 months (95% CI: 1.5‐2.9) in Part A (n = 109) and 4.2 months (95% CI: 1.7‐5.5) in Part B (n = 40). Median OS was 7.3 months (95% CI: 4.9‐10.5) in Part A and 16.8 months (95% CI: 10.5‐24.4) in Part B. OS was longer in AFP responders (>20% decrease from baseline, Part A) compared to non‐responders (21.5 months vs 6.8 months). OS was longer in TGF‐β1 responders (>20% decrease from baseline, all patients) compared to non‐responders. The most common Grade 3/4 treatment‐related adverse events were neutropenia (n = 4) and fatigue, anaemia, increased bilirubin, hypoalbuminemia and embolism (each, n = 2). Conclusions: Galunisertib treatment had a manageable safety profile in patients with HCC. Lower baseline AFP and a response in AFP or TGF‐β1 levels (vs no response) correlated with longer survival. Trial Registration Number: NCT01246986 at ClinicalTrials.gov.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.14113

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 142

Metadata

Authors
Faivre, S., Santoro, A., Kelley, R. K., Gane, E., Costentin, C. E., Gueorguieva, I., Smith, C., Cleverly, A., Lahn, M. M., Raymond, E., Benhadji, K. A., & Giannelli, G.
Venue
Liver International
Publisher
Wiley
Published
2019-06-03
Volume
39
Issue
8
Pages
1468-1477
ISSN
  • 0106-9543 (ISSN-L)
  • 1478-3223
  • 1478-3231
OpenAlex
W2937730750
Cited by
142
References
6
FWCI
9.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.